A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation
Clinical trial NCT00655161 · COMPLETED
Trial details
- NCT number
- NCT00655161
- Sponsor
- GlobeImmune
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2008-04-01
- Primary completion
- 2013-11-01
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.